ROSEN, A PIONEER IN INVESTOR REPRESENTATION, Urges Sage Therapeutics Shareholders to Establish Representation Ahead of Deadline in Class Action Lawsuit

The Rosen Law Firm, a premier global investor rights law firm, has issued a reminder to investors of Sage Therapeutics, Inc. SAGE, a company specializing in central nervous system disorders, regarding the approaching deadline for participating in a securities class action lawsuit. This notification targets individuals who purchased shares of Sage Therapeutics, Inc. SAGE between April 12, 2021, and July 23, 2024. The firm is advocating for shareholders to join the lawsuit ahead of the crucial deadline on October 28, 2024.

Understanding the Case

In the heart of Cambridge, Massachusetts stands Sage Therapeutics, Inc. SAGE, a biopharmaceutical company leading the charge in the development and commercialization of novel drug therapies. These medications are primarily aimed at treating various conditions affecting the central nervous system. However, significant concerns have risen regarding potential federal securities laws violations by the company during the specified period, sparking a legal battle spearheaded by the experienced Rosen Law Firm.

Legal Expertise and Investor Advocacy

The Rosen Law Firm is recognized for its dedication to defending shareholder rights. This expertise is particularly pertinent for investors of Sage Therapeutics, Inc. SAGE who may have been impacted financially by any alleged misconduct. The firm's call to action emphasizes the importance of the deadline, after which affected investors might forfeit their right to financial recoveries. Notably, the legal team remains resolute in seeking recompense for their clients, counting on a collective effort through this class-action suit.

Investment, Legal, Healthcare